SAGE Therapeutics Inc SAGE has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals.
It found further reason to celebrate Monday with the conversion of a new Street advocate.
Morgan Stanley analyst Matthew Harrison initiated coverage on Sage with an Overweight rating and $225 price target.
Sage is developing a pipeline of GABA-receptor agents to treat central nervous system diseases with a mechanism that's potentially faster, more widely applicable and has fewer pronounced side effects than current standards of care.
Brexanolone, Sage’s treatment for postpartum depression to be submitted to the U.S. Food and Drug Administration in the first half of the year, is expected to post peak U.S. sales of $775 million, Harrison said in a Monday note.
“Given the lack of standard treatment and the modest benefit available with generic antidepressants, we believe brexanolone can be a [nearly] $1 billion global drug,” the analyst said.
That compounds Sage’s long-term opportunity in SAGE-217, which is seen to have potential in depression, bipolar disorder and insomnia.
“We see continued derisking of '217 driving SAGE higher,” the analysts wrote, forecasting more than $2.5 billion in peak sales.
At the time of publication, shares were set to open up 1.4 percent at $166.50.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.